SCHEMBL4401760

SCHEMBL4401760

Cc1ccc(-c2cccc(-c3cccc(-c4ccc(C)cc4)n3)n2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.56
MEN1 O00255 5/20 0.56
RAB9A P51151 3/20 0.56
ALDH1A1 P00352 4/20 0.56
MAPT P10636 2/20 0.56
HPGD P15428 2/20 0.56
POLB P06746 2/20 0.56
HSD17B10 Q99714 1/20 0.56
CCR1 P32246 1/20 0.50
CCR8 P51685 1/20 0.50
KDM4E B2RXH2 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
ENPP3 O14638 1/20 0.47
ENPP1 P22413 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
SREBF2 Q12772 1/20 0.46
NPC1 O15118 2/20 0.45
MITF O75030 1/20 0.45
KDM5A P29375 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3421833 0.97 KMT2A (0.59) KMT2AMEN1RAB9AALDH1A1MAPT
SCHEMBL23921025 0.95 KMT2A (0.56) KMT2AMEN1RAB9AALDH1A1MAPT
SCHEMBL12339168 0.91 KMT2A (0.73) KMT2AMEN1RAB9AALDH1A1MAPT
SCHEMBL12339141 0.87 RAB9A (0.58) KMT2AMEN1RAB9AALDH1A1MAPT
SCHEMBL28345601 0.87 ACHE (0.54) KMT2AMEN1RAB9AALDH1A1MAPT
SCHEMBL4402501 0.87 MEN1 (0.47) KMT2AMEN1RAB9AALDH1A1MAPT
SCHEMBL7963741 0.86 KDM4E (0.67) KMT2AMEN1RAB9AALDH1A1HPGD
SCHEMBL2614970 0.86 CCR1 (0.65) KMT2AMEN1RAB9AALDH1A1MAPT
SCHEMBL4402810 0.85 MEN1 (0.46) KMT2AMEN1RAB9AALDH1A1MAPT
SCHEMBL15460386 0.83 NPC1 (0.49) KMT2AMEN1RAB9AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8877355-B2 Monoamine compound, charge-transporting material, and organic electroluminescent device MITSUBISHI CHEMICAL CORPORATION (JP) 2014-11-04 US disclosed
US-20130214263-A1 MONOAMINE COMPOUND, CHARGE-TRANSPORTING MATERIAL, AND ORGANIC ELECTROLUMINESCENT DEVICE MITSUBISHI CHEMICAL CORPORATION (JP) 2013-08-22 US disclosed
US-8427046-B2 Monoamine compound, charge-transporting material, and organic electroluminescent device MITSUBISHI CHEMICAL CORPORATION (JP) 2013-04-23 US disclosed
US-8337999-B2 Organic electroluminescent device including at least one layer containing an indole derivative UDC IRELAND LIMITED (IE) 2012-12-25 US disclosed
US-8168307-B2 Organic compound, charge transport material and organic electroluminescent device PIONEER CORPORATION (JP) 2012-05-01 US disclosed
US-20100026174-A1 ORGANIC ELECTROLUMINESCENT DEVICE FUJIFILM CORPORATION (JP) 2010-02-04 US disclosed
US-20090230846-A1 MONOAMINE COMPOUND, CHARGE-TRANSPORTING MATERIAL, AND ORGANIC ELECTROLUMINESCENT DEVICE MITSUBISHI CHEMICAL CORPORATION (JP) 2009-09-17 US disclosed
US-20090021146-A1 ORGANIC COMPOUND, CHARGE TRANSPORT MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE PIONEER CORPORATION (JP) 2009-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090021146-A1 ORGANIC COMPOUND, CHARGE TRANSPORT MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE SLC25A21, SLCO2A1, OCIAD2 KMT2A 1162/4885MEN1 1827/4885RAB9A 1941/4885
US-20090230846-A1 MONOAMINE COMPOUND, CHARGE-TRANSPORTING MATERIAL, AND ORGANIC ELECTROLUMINESCENT DEVICE SLC7A5, SLC18A1, MAOA KMT2A 982/4885MEN1 2206/4885RAB9A 362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.